At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Halozyme’s argenx expansion puts ENHANZE back in focus Halozyme Therapeutics (HALO) extended its ENHANZE collaboration with argenx to cover two more exclusive targets, taking the total to eight and adding fresh attention to the stock’s partnership-driven revenue model. Under the expanded agreement, Halozyme is eligible for milestone payments linked to development and commercial progress, as well as royalties on net sales of ENHANZE based products. This keeps investor focus on execution rather...

In late September 2026, a Dutch court ruled in favor of Halozyme Therapeutics, issuing an injunction that halts manufacture and sale of Merck’s subcutaneous Keytruda in eight European countries following a patent dispute. This setback affects one of Merck’s key immuno-oncology formulations in important European markets, highlighting how legal outcomes can directly influence product access and portfolio planning. We’ll now examine how this injunction affecting subcutaneous Keytruda in several...

Oct 7 (Reuters) - Biopharma company Halozyme said on Wednesday that a Dutch patent court ruled in its favor against Merck, ordering the drugmaker to halt the manufacture and sale of injectable

Un tribunal holandés prohibió a Merck vender Keytruda subcutáneo en varios países europeos. Por otra parte, un ejecutivo de Insmed puso fin a una carrera de siete años y dos nuevas empresas obtuvieron capital de riesgo.

Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.

/PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague...